Mechanisms of trauma-induced coagulopathy.
Nathan J White
https://pubmed.ncbi.nlm.nih.gov/24319248/Actively Recruiting
Led by Erasmus Medical Center · Updated on 2026-10-06
50
Participants Needed
1
Research Sites
N/A
Total Duration
Trauma-induced coagulopathy TIC is a serious complication in patients with severe injuries causing blood clotting problems and increased risk of death. Fibrinogen, a key protein for blood clotting, is often low in these patients and linked to injury severity. This study evaluates a new, faster point-of-care fibrinogen test to see if it can be used during emergency trauma care to improve decision-making compared to the current slower lab tests. The study involves adults aged 16 and older who have suffered serious trauma with active bleeding and for whom a massive transfusion protocol is activated. Blood samples used for routine tests will also be tested with the new point-of-care device, without extra blood draws. The test results will not affect current treatment as this is a feasibility study, but the time taken and any difficulties with the test will be recorded. Later, researchers will review whether having quick fibrinogen results could have altered treatment decisions and patient outcomes. Participants will be monitored during emergency care and data on transfusions, fibrinogen levels, vital signs, and survival up to 30 days will be collected anonymously. Nurses will record how quickly the test is done and any issues encountered. The study aims to see if the fast test can be practically performed in the emergency department and if it could lead to more tailored fibrinogen treatment, potentially improving outcomes and reducing unnecessary transfusions.
CONDITIONS
Point of Care Fibrinogen Measurement in Trauma Patients in the Emergency Department
N
Niki A. Ottenhof, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Erasmus Medical Center
Lead Sponsor
Diagnostica Stago R&D
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - During emergency department stay
Participants receive emergency trauma care while a small amount of blood is tested using the rapid fibrinogen test alongside routine tests. Nurses record the time taken and any difficulties with the test. The test results are not used for treatment decisions during the study.
Continuous monitoring during care
Duration - Up to 30 days after trauma
Researchers analyze collected data including fibrinogen levels, transfusion details, vital signs, injury severity, and survival outcomes to evaluate if rapid testing could have influenced clinical decisions and patient outcomes.
No participant visits; data collected from records
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Nathan J White
https://pubmed.ncbi.nlm.nih.gov/24319248/Erasmus Medical Center
Lead Sponsor
Diagnostica Stago R&D
Collaborating Sponsor